2026 Q1 -tulosraportti
Vain PDF
32 päivää sitten
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 23.9. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 24.6. | ||
2025 Q4 -tulosraportti 25.3. | ||
2025 Q3 -tulosraportti 26.11.2025 | ||
2025 Q2 -tulosraportti 17.9.2025 | ||
2025 Q1 -tulosraportti 27.6.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·1 t sittenSoftOx beyond CF-PoC in 2027: What if the value is greater than a single indication? The excitement surrounding SoftOx has gradually intensified towards the upcoming Proof-of-Concept (PoC) readout for SIS-03 in the first half of 2027. The company has already passed several important milestones: Dose escalation in healthy volunteers has been completed, the safety profile has been strengthened, and the transition to patients with chronic lung infections and cystic fibrosis (CF) is well underway. Much of the market's attention is now focused on one question: Will the CF study be a success? But perhaps it is also worth asking another question: What if the CF study simultaneously validates a technology that can be used far more broadly than CF alone? CF and the fight against biofilm Cystic fibrosis is not a randomly chosen indication. It is among the most demanding biological environments in which to test an inhalation treatment. Here, the treatment encounters: * Extremely viscous mucus * Chronic infections * Diseased and irritated lung tissue * Established biofilms (bacteria that wall themselves into a protective layer of mucus — one of the biggest nightmares in modern infectious medicine) If a technology shows clear biological activity under such conditions, it has practically passed one of the toughest exams there is. If SoftOx manages to penetrate the biofilm in CF lungs, they have demonstrated a property that can be relevant across a range of infection-related indications. Therefore, CF should not just be seen as a single market, but as the ultimate validation arena for the core technology. --- Undervalued asset: The powder platform One aspect that, in my opinion, receives too little attention is the powder technology itself. Historically, hypochlorous acid (HOCl) has had one major weakness: stability. In liquid form, the substance breaks down relatively quickly into saltwater. If SoftOx has solved this through a patent-protected powder formulation, it represents a value that extends far beyond the first lung indication. A stable powder can: * Be stored for long periods (shelf-stable) * Be easily transported worldwide * Be used without complicated logistics or cold chain * Be mixed on-site as needed Many promising antimicrobial substances throughout history have failed due to logistics, durability, or distribution. By moving HOCl from an unstable liquid to a stable powder, SoftOx has practically addressed the distribution bottleneck that has long limited the applicability of the substance. This could prove to be one of the most important underlying value drivers in the entire case. The defense axis is bigger than many think Through SoftOx Defense Solutions, collaboration with the Norwegian Defence Research Establishment (FFI), and grants from the European Defence Fund (EDF), the company has already gained a solid foothold in the defense sector. The potential areas of application here are very broad: * **Biological threats:** Rapid neutralization of acute pathogens such as bacteria, viruses, and persistent spores (e.g., anthrax), which are biologically much easier to handle when not protected by the body's own defense mucus. * Field medicine: Wound irrigation and infection control in the critical phase immediately after an injury, often referred to as "the golden hour". * Decontamination and fogging: Remediation of vehicles, tents, command posts, and sensitive equipment. The latter is particularly interesting. Traditional decontamination often uses very aggressive and corrosive chemicals. If stable HOCl can deliver the necessary effect with minimal impact on personnel, electronics, and materials, it represents a potentially very attractive alternative for military forces. An asymmetric investment story beyond PoC What makes SoftOx interesting is that the same technology can potentially be relevant in a number of different directions: * Chronic respiratory infections * Bronchiectasis * COPD-related infections * Wound treatment * Preparedness * Defense * Decontamination and remediation The interesting thing for investors is that several of these opportunity areas are built on the same technological cornerstones: stable HOCl, the powder formulation, and the ability to handle microbiological challenges in demanding environments. For me, therefore, the most interesting question is not just whether CF will be an immediate commercial homerun. The most interesting thing is whether the study helps to demonstrate that stable inhalable HOCl can actually deliver biological effect in one of the most demanding environments that exist. If the answer to that question is yes, it potentially opens more doors than the single indication the market is currently focusing on. Then, the CF study could retrospectively prove to be the first major validation of a broad technology platform, rather than just a study within a single disease.
·2 päivää sittenWhat do you think about this stock is there potentialI have great faith in this stock, must have a little patience, it is in the middle of trials now, when these start to yield some results (positive) then this will come like a rocket, I at least have great faith, anyway have a nice weekend and best of luck ❤️🌞
·20.7.It still looks like the algos have gone on vacation, low volume in the stock, little selling interest at this level. Slight increase so far but when people wake up from vacation I think we will move up slowly but surely. Will probably be a pit stop at 0.1050+/-
- ·17.7.It would have been nice with a typical Friday, closing on the plus side, anyway have a nice weekend and a continued good summer❤️🌞
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
Vain PDF
32 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·1 t sittenSoftOx beyond CF-PoC in 2027: What if the value is greater than a single indication? The excitement surrounding SoftOx has gradually intensified towards the upcoming Proof-of-Concept (PoC) readout for SIS-03 in the first half of 2027. The company has already passed several important milestones: Dose escalation in healthy volunteers has been completed, the safety profile has been strengthened, and the transition to patients with chronic lung infections and cystic fibrosis (CF) is well underway. Much of the market's attention is now focused on one question: Will the CF study be a success? But perhaps it is also worth asking another question: What if the CF study simultaneously validates a technology that can be used far more broadly than CF alone? CF and the fight against biofilm Cystic fibrosis is not a randomly chosen indication. It is among the most demanding biological environments in which to test an inhalation treatment. Here, the treatment encounters: * Extremely viscous mucus * Chronic infections * Diseased and irritated lung tissue * Established biofilms (bacteria that wall themselves into a protective layer of mucus — one of the biggest nightmares in modern infectious medicine) If a technology shows clear biological activity under such conditions, it has practically passed one of the toughest exams there is. If SoftOx manages to penetrate the biofilm in CF lungs, they have demonstrated a property that can be relevant across a range of infection-related indications. Therefore, CF should not just be seen as a single market, but as the ultimate validation arena for the core technology. --- Undervalued asset: The powder platform One aspect that, in my opinion, receives too little attention is the powder technology itself. Historically, hypochlorous acid (HOCl) has had one major weakness: stability. In liquid form, the substance breaks down relatively quickly into saltwater. If SoftOx has solved this through a patent-protected powder formulation, it represents a value that extends far beyond the first lung indication. A stable powder can: * Be stored for long periods (shelf-stable) * Be easily transported worldwide * Be used without complicated logistics or cold chain * Be mixed on-site as needed Many promising antimicrobial substances throughout history have failed due to logistics, durability, or distribution. By moving HOCl from an unstable liquid to a stable powder, SoftOx has practically addressed the distribution bottleneck that has long limited the applicability of the substance. This could prove to be one of the most important underlying value drivers in the entire case. The defense axis is bigger than many think Through SoftOx Defense Solutions, collaboration with the Norwegian Defence Research Establishment (FFI), and grants from the European Defence Fund (EDF), the company has already gained a solid foothold in the defense sector. The potential areas of application here are very broad: * **Biological threats:** Rapid neutralization of acute pathogens such as bacteria, viruses, and persistent spores (e.g., anthrax), which are biologically much easier to handle when not protected by the body's own defense mucus. * Field medicine: Wound irrigation and infection control in the critical phase immediately after an injury, often referred to as "the golden hour". * Decontamination and fogging: Remediation of vehicles, tents, command posts, and sensitive equipment. The latter is particularly interesting. Traditional decontamination often uses very aggressive and corrosive chemicals. If stable HOCl can deliver the necessary effect with minimal impact on personnel, electronics, and materials, it represents a potentially very attractive alternative for military forces. An asymmetric investment story beyond PoC What makes SoftOx interesting is that the same technology can potentially be relevant in a number of different directions: * Chronic respiratory infections * Bronchiectasis * COPD-related infections * Wound treatment * Preparedness * Defense * Decontamination and remediation The interesting thing for investors is that several of these opportunity areas are built on the same technological cornerstones: stable HOCl, the powder formulation, and the ability to handle microbiological challenges in demanding environments. For me, therefore, the most interesting question is not just whether CF will be an immediate commercial homerun. The most interesting thing is whether the study helps to demonstrate that stable inhalable HOCl can actually deliver biological effect in one of the most demanding environments that exist. If the answer to that question is yes, it potentially opens more doors than the single indication the market is currently focusing on. Then, the CF study could retrospectively prove to be the first major validation of a broad technology platform, rather than just a study within a single disease.
- ·2 päivää sittenWhat do you think about this stock is there potentialI have great faith in this stock, must have a little patience, it is in the middle of trials now, when these start to yield some results (positive) then this will come like a rocket, I at least have great faith, anyway have a nice weekend and best of luck ❤️🌞
- ·20.7.It still looks like the algos have gone on vacation, low volume in the stock, little selling interest at this level. Slight increase so far but when people wake up from vacation I think we will move up slowly but surely. Will probably be a pit stop at 0.1050+/-
- ·17.7.It would have been nice with a typical Friday, closing on the plus side, anyway have a nice weekend and a continued good summer❤️🌞
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 23.9. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 24.6. | ||
2025 Q4 -tulosraportti 25.3. | ||
2025 Q3 -tulosraportti 26.11.2025 | ||
2025 Q2 -tulosraportti 17.9.2025 | ||
2025 Q1 -tulosraportti 27.6.2025 |
2026 Q1 -tulosraportti
Vain PDF
32 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 23.9. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 24.6. | ||
2025 Q4 -tulosraportti 25.3. | ||
2025 Q3 -tulosraportti 26.11.2025 | ||
2025 Q2 -tulosraportti 17.9.2025 | ||
2025 Q1 -tulosraportti 27.6.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·1 t sittenSoftOx beyond CF-PoC in 2027: What if the value is greater than a single indication? The excitement surrounding SoftOx has gradually intensified towards the upcoming Proof-of-Concept (PoC) readout for SIS-03 in the first half of 2027. The company has already passed several important milestones: Dose escalation in healthy volunteers has been completed, the safety profile has been strengthened, and the transition to patients with chronic lung infections and cystic fibrosis (CF) is well underway. Much of the market's attention is now focused on one question: Will the CF study be a success? But perhaps it is also worth asking another question: What if the CF study simultaneously validates a technology that can be used far more broadly than CF alone? CF and the fight against biofilm Cystic fibrosis is not a randomly chosen indication. It is among the most demanding biological environments in which to test an inhalation treatment. Here, the treatment encounters: * Extremely viscous mucus * Chronic infections * Diseased and irritated lung tissue * Established biofilms (bacteria that wall themselves into a protective layer of mucus — one of the biggest nightmares in modern infectious medicine) If a technology shows clear biological activity under such conditions, it has practically passed one of the toughest exams there is. If SoftOx manages to penetrate the biofilm in CF lungs, they have demonstrated a property that can be relevant across a range of infection-related indications. Therefore, CF should not just be seen as a single market, but as the ultimate validation arena for the core technology. --- Undervalued asset: The powder platform One aspect that, in my opinion, receives too little attention is the powder technology itself. Historically, hypochlorous acid (HOCl) has had one major weakness: stability. In liquid form, the substance breaks down relatively quickly into saltwater. If SoftOx has solved this through a patent-protected powder formulation, it represents a value that extends far beyond the first lung indication. A stable powder can: * Be stored for long periods (shelf-stable) * Be easily transported worldwide * Be used without complicated logistics or cold chain * Be mixed on-site as needed Many promising antimicrobial substances throughout history have failed due to logistics, durability, or distribution. By moving HOCl from an unstable liquid to a stable powder, SoftOx has practically addressed the distribution bottleneck that has long limited the applicability of the substance. This could prove to be one of the most important underlying value drivers in the entire case. The defense axis is bigger than many think Through SoftOx Defense Solutions, collaboration with the Norwegian Defence Research Establishment (FFI), and grants from the European Defence Fund (EDF), the company has already gained a solid foothold in the defense sector. The potential areas of application here are very broad: * **Biological threats:** Rapid neutralization of acute pathogens such as bacteria, viruses, and persistent spores (e.g., anthrax), which are biologically much easier to handle when not protected by the body's own defense mucus. * Field medicine: Wound irrigation and infection control in the critical phase immediately after an injury, often referred to as "the golden hour". * Decontamination and fogging: Remediation of vehicles, tents, command posts, and sensitive equipment. The latter is particularly interesting. Traditional decontamination often uses very aggressive and corrosive chemicals. If stable HOCl can deliver the necessary effect with minimal impact on personnel, electronics, and materials, it represents a potentially very attractive alternative for military forces. An asymmetric investment story beyond PoC What makes SoftOx interesting is that the same technology can potentially be relevant in a number of different directions: * Chronic respiratory infections * Bronchiectasis * COPD-related infections * Wound treatment * Preparedness * Defense * Decontamination and remediation The interesting thing for investors is that several of these opportunity areas are built on the same technological cornerstones: stable HOCl, the powder formulation, and the ability to handle microbiological challenges in demanding environments. For me, therefore, the most interesting question is not just whether CF will be an immediate commercial homerun. The most interesting thing is whether the study helps to demonstrate that stable inhalable HOCl can actually deliver biological effect in one of the most demanding environments that exist. If the answer to that question is yes, it potentially opens more doors than the single indication the market is currently focusing on. Then, the CF study could retrospectively prove to be the first major validation of a broad technology platform, rather than just a study within a single disease.
- ·2 päivää sittenWhat do you think about this stock is there potentialI have great faith in this stock, must have a little patience, it is in the middle of trials now, when these start to yield some results (positive) then this will come like a rocket, I at least have great faith, anyway have a nice weekend and best of luck ❤️🌞
- ·20.7.It still looks like the algos have gone on vacation, low volume in the stock, little selling interest at this level. Slight increase so far but when people wake up from vacation I think we will move up slowly but surely. Will probably be a pit stop at 0.1050+/-
- ·17.7.It would have been nice with a typical Friday, closing on the plus side, anyway have a nice weekend and a continued good summer❤️🌞
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt